Loading company…
Reverie Labs used computational chemistry and machine learning to develop medicines.
Reverie Labs developed a drug discovery platform using computational chemistry and machine learning, including kinase inhibitor programs such as RVL-101, RVL-1-2 and RVL-103. Founded in Massachusetts in 2017, the company was acquired by Ginkgo Bioworks in February 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in